InvestSMART

Algorae Pharmaceuticals Limited (ASX:1AI)

ALERT: Price-sensitive ASX Announcement for 1AI
Current share price for 1AI : $0.011 -0.003 (-21.43%)+
Announcement
Release
6 May 2026 8:54AM
Price at Release
$0.014
Full Release
download
Summary
Algorae Pharmaceuticals Limited has announced its execution of a License & Supply Agreement with Torrent Pharmaceuticals to commercialise two generic prescription molecules in Australia and New Zealand. The agreement outlines a phased commercialisation strategy, beginning with products that have existing regulatory registrations, allowing for an earlier market entry. A subsequent phase will focus on products requiring new Therapeutic Goods Administration (TGA) registrations, forming a long-term launch pipeline. AlgoraeRx Pty Ltd, a subsidiary of Algorae, will lead market access and commercialisation activities in the region, with Torrent Pharmaceuticals responsible for product development and manufacturing. The agreement also sets a strategic framework for potentially including additional molecules in future phases, subject to mutual agreement. The commercial terms remain confidential, and updates will be provided as the program progresses.
Key Points
  • Algorae executes a Licence & Supply Agreement with Torrent Pharmaceuticals.
  • The agreement involves two generic prescription molecules for Australia and New Zealand.
  • Phased commercialisation strategy outlined with products supported by existing registrations.
  • Future phases target products requiring new TGA registrations.
  • AlgoraeRx to lead market access and commercialisation activities in Australia and New Zealand.
  • Torrent responsible for product development and GMP compliant manufacturing.
  • Strategic framework established for additional molecules in future phases.
  • Commercial terms are confidential with updates to be provided on progress.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.